Key statistics
On Thursday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 16.52, -12.59% below its 52-week high of 18.90, set on Jun 27, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.75 |
---|---|
High | 16.81 |
Low | 16.15 |
Bid | 16.09 |
Offer | 16.85 |
Previous close | 16.75 |
Average volume | 1.90m |
---|---|
Shares outstanding | 98.21m |
Free float | 74.55m |
P/E (TTM) | -- |
Market cap | 1.62bn USD |
EPS (TTM) | -0.2536 USD |
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
- ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
- ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
- ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
- ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
- ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
- ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences
- ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients
- ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
More ▼